Project Grant R44AI170331
Award Date 3/10/22
Completion Date 2/28/25
Dollars Obligated $6M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Malvern, PA 19355, USA
Similar Awards
- This National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase I award to Bactria Pharmaceuticals LLC is providing $274,937 to develop therapeutic drugs that restore antibiotic sensitivity in bacteria that cause severe healthcare-associated infections. The goal is to combat antimicrobial resistance in gram-negative pathogens through the use of small molecule efflux pump inhibitors (EPIs). The project involves three key activities: cryo-electron microscopy to understand...
- This Project Grant award of $300,000 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research by Fimbrion Therapeutics Inc. to develop small molecule glycoside inhibitors targeting the LecB lectin protein in Pseudomonas aeruginosa (PA) bacteria. The goal is to create novel therapeutics to disrupt PA biofilm formation and enhance the efficacy of antibiotics in treating PA infections,...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 aims to develop a platform for detecting genetic antibiotic resistance motifs that can predict current and future susceptibility to therapeutics. The project will establish the feasibility of leveraging mutational signatures in bacterial DNA to identify antibiotic resistance status, including the potential for rapid development of multi-drug resistance. This approach...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Program (CFDA 93.855) aims to develop a new rapid method for determining antibiotic susceptibility of bloodborne bacterial infections. The $1,795,199 grant, awarded on August 1, 2025, will fund the creation of a "Phenotypically Amplified Beta-Lactamase (PHABL) Assay" to detect beta-lactamase-producing pathogens within hours instead...
- The National Science Foundation (NSF) awarded a $305,000 SBIR Phase I Project Grant to Giant Biosystems Inc. on March 1, 2025. The project aims to develop a rapid, point-of-care antimicrobial susceptibility testing (AST) kit that can provide results on the same day a sample is taken. This is expected to help physicians utilize the most effective antibiotics sooner, reducing antimicrobial resistance and associated economic burdens. The proposed microfluidic platform is designed to generate...
- This Project Grant award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $305,000.00 to Resonantia Diagnostics, Inc. to develop a transformative diagnostic platform for rapid identification and antimicrobial susceptibility testing of pathogens. The project aims to achieve three key technical objectives: (1) demonstrate accurate antimicrobial susceptibility testing at very low pathogen loads, (2) validate testing...
- This federal Project Grant award of $451,000.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) to The Trustees of Princeton University supports research to identify new antimicrobial targets in gram-negative bacterial pathogens using chemical synthetic lethality. The key objectives are to: 1) Identify a small molecule inhibitor of methionine synthase, a recently identified essential target in Burkholderia pseudomallei, when...
- This Project Grant award from the National Science Foundation's Integrative Activities (IA) program provides $275,000 to Clemson University to develop a flexible, tunable voltammetric sensor that can rapidly detect and quantify virulence signals from the Pseudomonas aeruginosa bacteria. The goal is to enable faster determination of infections caused by antibiotic-resistant bacteria, which annually lead to more than 35,000 deaths in the U.S. despite widespread antibiotic availability. The...
- This $747,763 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to develop small molecule inhibitors of the LpxH enzyme as novel antibiotics for treating multidrug-resistant Enterobacterales infections, such as those caused by extended-spectrum beta-lactamase (ESBL)-producing and carbapenem-resistant Enterobacterales (CRE). The goal is to design and synthesize potent LpxH inhibitors with...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $254,478 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The University of Texas Southwestern Medical Center to identify mechanisms of resistance to pathogen-specific antibacterial antisense compounds and develop strategies to circumvent them. The project aims to determine the resistance mechanisms for lead peptide-phosphorodiamidate morpholino oligomers (PPMOs) against...